Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([¹³¹I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1).

ABSTRACT:

Background

Glioblastoma (GBM), the most common malignant brain tumor, is associated with devastating outcomes. IPAX-1 was a multicenter, open-label, single-arm phase I study to evaluate carrier-added 4-L-[¹³¹I]iodo-phenylalanine ([¹³¹I]IPA) plus external radiation therapy (XRT) in recurrent GBM.

Methods

A total of 10 adults with recurrent GBM who had received first-line debulking surgery plus radio-chemotherapy, were randomized to a single-dose regimen (1f; ¹³¹I-IPA 2 GBq before XRT); a fractionated parallel dose regimen (3f-p; 3 ¹³¹I-IPA 670 MBq fractions, in parallel with second-line XRT), or a fractionated sequential dose regimen (3f-s; 3 ¹³¹I-IPA 670 MBq fractions before and after XRT). Metabolic tumor respons

SUBMITTER: Pichler J 

PROVIDER: S-EPMC11358817 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature